Bonus Issue of Equity Shares: Kilitch Drugs (I) Ltd

Kilitch Drugs (I) Ltd has announced a Bonus Issue of Equity Shares as part of its corporate action. Trading members and investors are informed that the company has fixed the Record Date to determine shareholder eligibility for the bonus issue. The equity shares of the company will trade on an Ex-Bonus basis from the date mentioned below.

Details of Corporate Action

Impact on Shareholding

Shareholders holding equity shares of Kilitch Drugs (I) Ltd as on the Record Date (24 March 2026) will be eligible to receive bonus shares in the 1:1 ratio. This means eligible investors will receive one additional equity share for every one share held.

While the number of shares held by investors will increase, the overall investment value generally remains proportionately unchanged, subject to market price adjustment post the bonus issue.

Allotment Information

As per company intimation, a total of 74,60,672 equity shares will be allotted on 25 March 2026 pursuant to the bonus issue. Trading in the equity shares will be on an Ex-Bonus basis from 24 March 2026.

Note

A bonus issue is a corporate action in which a company distributes additional shares to its existing shareholders free of cost by capitalizing its reserves. Post the bonus issue, the share price typically adjusts downward to reflect the increased number of shares, without impacting the company’s fundamentals.

Conclusion

The bonus issue by Kilitch Drugs (I) Ltd reflects the company’s effort to reward shareholders and enhance stock liquidity. The 1:1 bonus ratio will increase the number of shares outstanding and may improve trading activity in the stock.